AustCancer subsidiary signs distribution deal

By Renate Krelle
Tuesday, 06 July, 2004

ACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.

Under the deal, wholesale drug cooperative Rochester Drug Cooperative will stock revisys in more than eight hundred community retail pharmacies long-term care pharmacies and home health care stores in New York State, Pennsylvania and New Jersey.

Related News

Using your brain at work may ward off cognitive impairment

The harder your brain works at your job, the less likely you may be to have memory and thinking...

Repurposed drugs show promise in heart muscle regeneration

The FDA-approved medications, when given in combination, target two proteins that regulate the...

A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...

Content from other channels on our network

Enhancing primary care with data-driven clinical support

Collaboration key to improving adherence to physical activity guidelines

Alfred Health trials eye-tracking tech to assess brain function

Could UV light protect against hospital infections?

Australian regions with high cardiac arrest rates and low CPR: study

Tackling plastic waste in health care

Heat recovery could save money and the environment

How the perfect blend of tyres and plastic led to a sulfur-free oil

From glass waste to energy-efficient bricks

Could carbon financing boost green wastewater treatment?

ABAC updates guidance for digital marketing of alcohol

US policy change for raw breaded stuffed poultry products

Octopus inspires new gripper mechanism for robots

Pringles reduces height of can but not the chip content

Five consumer trends in the dairy market and beyond

All content Copyright © 2024 Westwick-Farrow Pty Ltd